Typical and atypical antipsychotic drug effects on locomotor hyperactivity and deficits in sensorimotor gating in a genetic model of NMDA receptor hypofunction

Pharmacology Biochemistry and Behavior

Volumn 85, Issue 3, 2006, Pages 481-491

  Duncan, Gary E ^a   Moy, Sheryl S ^a   Lieberman, Jeffrey A ^a   Koller, Beverly H ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Acoustic startle; Animal model; Haloperidol; Locomotor activity; NMDA receptor; Olanzapine; Prepulse inhibition; Risperidone; Schizophrenia

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; HALOPERIDOL; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 1; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NEUROLEPTIC AGENT; OLANZAPINE; RISPERIDONE;

ACOUSTICS; AMPLITUDE MODULATION; ANIMAL EXPERIMENT; ARTICLE; BEHAVIOR CHANGE; CONTROLLED STUDY; DOPAMINE RECEPTOR BLOCKING; DRUG EFFECT; GENETIC MODEL; HYPERACTIVITY; LOCOMOTION; MOUSE; MOUSE MUTANT; MOUSE STRAIN; NONHUMAN; PATHOPHYSIOLOGY; PREPULSE INHIBITION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SENSORIMOTOR FUNCTION; STARTLE REFLEX; STRAIN DIFFERENCE; WILD TYPE;

ANIMALS; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; EXCITATORY AMINO ACID ANTAGONISTS; HALOPERIDOL; MICE; MICE, INBRED C57BL; MICE, INBRED DBA; MODELS, ANIMAL; MOTOR ACTIVITY; RECEPTORS, N-METHYL-D-ASPARTATE; RISPERIDONE; STARTLE REACTION;

ANIMALIA; MUS;

EID: 33846240932     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pbb.2006.09.017     Document Type: Article

References (41)

1. Acri J.B., Morse D.E., Popke E.J., and Grunberg N.E. Nicotine increases sensory gating measured as inhibition of the acoustic startle reflex in rats. Psychopharmacology 114 (1994) 369-374
2. Bakshi V.P., and Geyer M.A. Antagonism of phencyclidine-induced deficits in prepulse inhibition by the putative atypical antipsychotic olanzapine. Psychopharmacology 122 (1995) 198-201
3. Bakshi V.P., Swerdlow N.R., and Geyer M.A. Clozapine antagonizes phencyclidine-induced deficits in sensorimotor gating of the startle response. Exp Clin Psychopharmacol 271 (1994) 787-794
4. Ballard T.M., Pauly-Evers M., Higgins G.A., Ouagazzal A.M., Mutel V., Borroni E., et al. Severe impairment of NMDA receptor function in mice carrying targeted point mutations in the glycine binding site results in drug-resistant nonhabituating hyperactivity. J Neurosci 22 (2002) 6713-6723
5. Braff D.L., Geyer M.A., and Swerdlow N.R. Human studies of prepulse inhibition of startle: normal subjects, patient groups, and pharmacological studies. Psychopharmacology 156 (2001) 234-258
6. Brody S.A., Conquet F., and Geyer M.A. Disruption of prepulse inhibition in mice lacking mGluR1. Eur J Neurosci 18 (2003) 3361-3366
7. Brody S.A., Geyer M.A., and Large C.H. Lamotrigine prevents ketamine but not amphetamine-induced deficits in prepulse inhibition in mice. Psychopharmacology 169 (2003) 240-246
8. Brody S.A., Conquet F., and Geyer M.A. Effect of antipsychotic treatment on the prepulse inhibition deficit of mGluR5 knockout mice. Psychopharmacology 172 (2004) 187-195
9. Cohen B.D., Rosenbaum G., Luby E.D., and Gottlieb J.S. Comparison of phencyclidine hydrochloride (sernyl) with other drugs: simulation of schizophrenic performance with phencyclidine hydrochloride (sernyl)lysergic acid diethylamide (LSD - 25), and amobarbital (Amytal) sodium, II - symbolic and sequential thinking. Arch Gen Psychiatry 6 (1962) 79-85
10. Duncan G.E., Zorn S., and Lieberman J.A. Mechanisms of typical and atypical antipsychotic drug action in relation to dopamine and NMDA receptor hypofunction hypotheses of schizophrenia. Mol Psychiatry 4 (1999) 418-428
11. Duncan G.E., Miyamoto S., Gu H.B., Lieberman J.A., Koller B.H., and Snouwaert J.N. Alterations in regional brain metabolism in genetic and pharmacological models of reduced NMDA receptor function. Brain Res 951 (2002) 166-176
12. Duncan G.E., Moy S.S., Perez A., Eddy D.M., Zinzow W.M., Lieberman J.A., et al. Deficits in sensorimotor gating and tests of social behavior in a genetic model of reduced NMDA receptor function. Behav Brain Res 153 (2004) 507-519
13. Duncan G.E., Moy S.S., Lieberman J.A., and Koller B.H. Effects of haloperidol, clozapine, and quetiapine on sensorimotor gating in a genetic model of reduced NMDA receptor function. Psychopharmacology 184 (2006) 190-200
14. Fradley R.L., O'Meara G.F., Newman R.J., Andrieux A., Job D., and Reynolds D.S. STOP knockout and NMDA NR1 hypomorphic mice exhibit deficits in sensorimotor gating. Behav Brain Res 163 (2005) 257-264
15. Keith V.A., Mansbach R.S., and Geyer M.A. Failure of haloperidol to block the effects of phencyclidine and dizocilpine on prepulse inhibition of startle. Biol Psychiatry 30 (1991) 557-566
16. Kinkead B., Dobner P.R., Egnatashvili V., Murray T., Deitemeyer N., and Nemeroff C.B. Neurotensin-deficient mice have deficits in prepulse inhibition: restoration by clozapine but not haloperidol, olanzapine, or quetiapine. J Pharmacol Exp Ther 315 (2005) 256-264
17. Krystal J.H., Karper L.P., Seibyl J.P., Freeman G.K., Delaney R., Bremner J.D., et al. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry 51 (1994) 199-214
18. Lahti A.C., Holcomb H.H., Medoff D.R., and Tamminga C.A. Ketamine activates psychosis and alters limbic blood flow in schizophrenia. Neuroreport 6 (1995) 869-872
19. Lahti A.C., Koffel B., LaPorte D., and Tamminga C.A. Subanesthetic doses of ketamine stimulate psychosis in schizophrenia. Neuropsychopharmacology 13 (1995) 9-19
20. Lahti A.C., Weiler M.A., Tamara M.B., Parwani A., and Tamminga C.A. Effects of ketamine in normal and schizophrenic volunteers. Neuropsychopharmacology 25 (2001) 455-467
21. Lipina T., Labrie V., Weiner I., and Roder J. Modulators of the glycine site on NMDA receptors, D-serine and ALX 5407, display similar beneficial effects to clozapine in mouse models of schizophrenia. Psychopharmacology 179 (2005) 54-67
22. Long L.E., Malone D.T., and Taylor D.A. Cannabidiol reverses MK-801-induced disruption of prepulse inhibition in mice. Neuropsychopharmacology 31 (2006) 795-803
23. Luby E.D., Cohen B.D., Rosenbaum G., Gottilieb J.S., and Kelley R. Study of a new schizophrenomimeitc drug-sernyl. Arch Neurol Psych 81 (1959) 363-369
24. Malhotra A.K., Pinals D.A., Weingartner H., Sirocco K., Missar C.D., Pickar D., et al. NMDA receptor function and human cognition - the effects of ketamine in healthy volunteers. Neuropsychopharmacology 14 (1996) 301-307
25. Malhotra A.K., Pinals D.A., Adler C.M., Elman I., Clifton A., Pickar D., et al. Ketamine-induced exacerbation of psychotic symptoms and cognitive impairment in neuroleptic-free schizophrenics. Neuropsychopharmacology 17 (1997) 141-150
26. Mansbach R.S. Effects of NMDA receptor ligands on sensorimotor gating in the rat. Eur J Pharmacol 202 (1991) 61-66
27. Mansbach R.S., and Geyer M.A. Effects of phencyclidine and phencyclidine biologs on sensorimotor gating in the rat. Neuropsychopharmacology 2 (1989) 299-308
28. Mansbach R.S., Carver J., and Zorn S.H. Blockade of drug-induced deficits in prepulse inhibition of acoustic startle by ziprasidone. Pharmacol Biochem Behav 69 (2001) 535-542
29. Miyamoto Y., Yamada K., Noda Y., Mori H., Mishina M., and Nabeshima T. Hyperfunction of dopaminergic and serotonergic neuronal systems in mice lacking the NMDA receptor epsilon 1 subunit. J Neurosci 21 (2001) 750-757
30. Miyamoto S., Snouwaert J.N., Koller B.H., Moy S.S., Lieberman J.A., and Duncan G.E. Amphetamine-induced Fos is reduced in limbic cortical regions but not in the caudate or accumbens in a genetic model of NMDA receptor hypofunction. Neuropsychopharmacology 29 (2004) 2180-2188
31. Mohn A.R., Gainetdinov R.R., Caron M.G., and Koller B.H. Mice with reduced NMDA receptor expression display behaviors related to schizophrenia. Cell 98 (1999) 427-436
32. Moy S.S., Perez A., Koller B.H., and Duncan G.E. Amphetamine-induced disruption of prepulse inhibition in mice with reduced NMDA receptor function. Brain Res 1089 (2006) 186-194
33. Olivier B., Leahy C., Mullen T., Paylor R., Groppi V.E., Sarnyai Z., et al. The DBA/2J strain and prepulse inhibition of startle: a model system to test antipsychotics?. Psychopharmacology 156 (2001) 284-290
34. Ouagazzal A.M., Jenck F., and Moreau J.L. Drug-induced potentiation of prepulse inhibition of acoustic startle reflex in mice: a model for detecting antipsychotic activity?. Psychopharmacology 156 (2001) 273-283
35. Paylor R., and Crawley J.N. Inbred strain differences in prepulse inhibition of the mouse startle response. Psychopharmacology 132 (1997) 169-180
36. Schreiber R., Dalmus M., and De Vry J. Effects of alpha(4)/beta(2)- and alpha(7)-nicotine acetylcholine receptor agonists on prepulse inhibition of the acoustic startle response in rats and mice. Psychopharmacology 159 (2002) 248-257
37. Simon V.M., Parra A., Minarro J., Arenas M.C., Vinader-Caerols C., and Aguilar M.A. Predicting how equipotent doses of chlorpromazine, haloperidol, sulpiride, raclopride and clozapine reduce locomotor activity in mice. Eur Neuropsychopharmacol 10 (2000) 159-164
38. Swerdlow N.R., Bakshi V.P., and Geyer M.A. Seroquel restores sensorimotor gating in phencyclidine-treated rats. J Pharmacol Exp Ther 279 (1996) 1290-1299
39. Swerdlow N.R., Bakshi V., Waikar M., Taaid N., and Geyer M.A. Seroquel, clozapine and chlorpromazine restore sensorimotor gating in ketamine-treated rats. Psychopharmacologia 140 (1998) 75-80
40. Tada M., Shirakawa K., Matsuoka N., and Mutoh S. Combined treatment of quetiapine with haloperidol in animal models of antipsychotic effect and extrapyramidal side effects: comparison with risperidone and chlorpromazine. Psychopharmacology 176 (2004) 94-100
41. Zhang W., and Bymaster F.P. The in vivo effects of olanzapine and other antipsychotic agents on receptor occupancy and antagonism of dopamine D-1, D-2, D-3, 5HT(2A) and muscarinic receptors. Psychopharmacology 141 (1999) 267-278